• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Opportunities for Easing BTK Inhibitor Switches

Opinion
Video

Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of multiple challenges including optimal timing of the switch, potential washout periods, dose adjustments, patient education about expected adverse effects, and close monitoring during the transition period to maintain treatment efficacy while minimizing complications.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
Barry Byrne, MD
Giulio Cossu, MD
Dr Toon Van Gorp
5 experts are featured in this series
5 experts are featured in this series
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.